With respect to assay development, quality assurance and, ultimately, clinical adoption, the primary subject of this review, these advantages are critical. Implicit with these advantages, TMAs enable ...
Breast cancer continues to impact millions worldwide, and for many, the diagnosis involves a hormone receptor-positive subtype. 1 These cancers rely on estrogen or progesterone to grow, using hormone ...
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...
Introduction: The estrogen receptor (ER) is routinely assessed by immunohistochemistry (IHC) in breast cancer to stratify patients into therapeutic and prognostic groups. Pathology laboratories are ...
The Fibroblast growth factor receptors 3-transforming acidic coiled-coil-containing protein 3 (FGFR3-TACC3, F3-T3) oncogenic fusion gene, identified in malignant tumors such as gliomas and bladder ...
EYSINS, Switzerland, April 3, 2025 /PRNewswire/ --Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® ...
The objective of the Tissue Resources Core is to collect, prepare and distribute high-quality human tissue samples (including solid tissues, blood and other biospecimens) to researchers located on the ...
Abstract: Tissue microarray (TMA) assessment of histomorphological biomarkers contributes to more accurate prediction of outcome of patients with colorectal cancer (CRC), a common disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results